Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 158   

Articles published

BMY 65.26 +0.26 (0.40%)
price chart
Bristol-Myers Squibb Co to Issue Quarterly Dividend of $0.37 on May 1st (BMY)
Analysts at Leerink Swann raised their price target on shares of Bristol-Myers Squibb from $72.00 to $73.50 and gave the company an �outperform� rating in a research note on Thursday, March 12th. Analysts at TheStreet downgraded shares of Bristol-Myers ...
Bristol-Myers Squibb Receives "AA-" Credit Rating from Morningstar ...  Dakota Financial News
Bristol-Myers Squibb to Announce Results for First Quarter 2015 on April 28  Business Wire (press release)
Bristol-Myers Squibb Co. Is Back in the Hepatitis C Race
Bristol-Myers Squibb Co. (NYSE: BMY ) took an intriguing approach to developing its hepatitis C drug, daclatasvir. Rather than focus its trials on the United States, the globe's biggest market for spending on medicine, it concentrated trials on Japan ...
Bristol-Myers Squibb EVP Francis M. Cuss Sells 114666 Shares (BMY)  Dakota Financial News
Louis S. Schmukler Sells 12000 Shares of Bristol-Myers Squibb Stock (BMY)  The Legacy
Merck & Co., Inc. Keytruda Beats Bristol-Myers Squibb Co Yervoy In Head-To ...
Merck & Co., Inc. (NYSE:MRK), the second-largest US drug maker, has another victory to add to its success story. Its cancer drug Keytruda has been proved to be superior than Bristol-Myers Squibb Co's (BMY) Yervoy, for treating patients of advanced ...
Keytruda Meets Study Goals as Advanced Melanoma Treatment, Merck Says  Wall Street Journal
Merck in $10B Buyback; Keytruda Tops Melanoma Study  Zacks.com
FDA Approves Bristol-Myers Squibb's Opdivo for Lung Cancer
U.S. regulators approved Bristol-Myers Squibb Co.'s advanced lung cancer drug Opdivo, the latest of a string of events that has focused efforts on using the immune system to battle the disease.
Bristol-Myers Squibb Co to Issue $0.37 Quarterly Dividend (BMY)  The Legacy
Bristol-Myers Squibb Co, Sanofi SA (ADR), and Novartis AG (ADR) Lead 2015 ...
Bristol-Myers Squibb Co (NYSE:BMY), Sanofi SA (ADR)(NYSE:SNY), and Novartis AG's (ADR)(NYSE:NVS) will be 2015's most valuable new drug launches, says a report published on Monday.
New Blockbuster Drugs Expected From Sanofi SA (ADR) (NYSE:SNY), Bristol ...  NYSE Post
Bristol, Sanofi and Novartis drugs to shine among 2015 launches  Reuters UK
Pfizer Inc. (NYSE:PFE) and Bristol-Myers Squibb Co. (NYSE:BMY); Which ...
Two important dividend pharma stocks that have been adversely affected by this patent cliff are Pfizer Inc. (NYSE:PFE) and Bristol-Myers Squibb Co. (NYSE:BMY). The gross income of Pfizer Inc. (NYSE:PFE) that is generated annually saw a decrease of 4%.
Better Dividend Stock: Pfizer Inc. vs. Bristol-Myers Squibb Co.  Motley Fool
Bristol-Myers Squibb Announces Acceptance of New Drug Application for ...  MarketWatch
Downtrend of Stocks: Bristol-Myers Squibb (NYSE:BMY), Finisar (NASDAQ ...
On Wed, Mar 25, 2015 Bristol-Myers Squibb Co (NYSE:BMY) proclaimed the company has signed an agreement with Novo Nordisk under which Bristol-Myers Squibb will acquire an exclusive global license to a discovery biologics research program focused ...
Bristol-Myers Squibb Co. Drug For Lung Cancer Gets FDA Nod
Bristol-Myers Squibb Co. (NYSE:BMY)'s share prices were found climbing an unprecedented high of 5% when the FDA approved its 'Opdivo' to fight lung cancer.
Bristol-Myers Squibb Lung Cancer Drug Approved By The FDA  Tech Times
FDA Surprises Everyone With Super-Fast Opdivo Lung Cancer Approval  Seeking Alpha (registration)
Pharma Equities Technical Data - Merck, AbbVie, Bristol-Myers Squibb, Eli ...
Bristol-Myers Squibb Co.'s stock declined 1.41%, to close the day at $65.12. The stock recorded a trading volume of 6.53 million shares, above its three months average volume of 6.33 million shares.
8 Healthcare Names Cowen & Co Are Talking About
Following a meeting with big cap pharma companies at its 35th Annual Health Care Conference, Cowen & Co published a report Tuesday detailing its key findings.